Erratum: A Kinase-Independent Function of CDK6 Links the Cell Cycle to Tumor Angiogenesis (Cancer Cell (2013) 24(2) (167–181) (S1535610813003218) (10.1016/j.ccr.2013.07.012));A kinase-independent function of CDK6 links the cell cycle to tumor angiogenesis

Cancer Cell

Volumn 24, Issue 2, 2013, Pages 167-181

  Kollmann, Karoline ^a   Heller, Gerwin ^b   Schneckenleithner, Christine ^a   Warsch, Wolfgang ^a   Scheicher, Ruth ^a   Ott, ReneG ^b   Schäfer, Markus ^d   Fajmann, Sabine ^a   Schlederer, Michaela ^b   Schiefer, Ana Iris ^b   Reichart, Ursula ^a   Mayerhofer, Matthias ^b   Hoeller, Christoph ^c   Zöchbauer Müller, Sabine ^b   Kerjaschki, Dontscho ^b   Bock, Christoph ^e   Kenner, Lukas ^f   Hoefler, Gerald ^g   Freissmuth, Michael ^b   Green, AnthonyR ^h,i,j   Moriggl, Richard ^f   Busslinger, Meinrad ^b   Malumbres, Marcos ^k   Sexl, Veronika ^a   more..

^a UNIVERSITY OF VETERINARY MEDICINE   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c Universitatsklinik fur Dermatologie   (Austria)

^d RESEARCH INSTITUTE OF MOLECULAR PATHOLOGY   (Austria)

^e ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

^f MEDICAL UNIVERSITY OF VIENNA   (Austria)

^g MEDICAL UNIVERSITY OF GRAZ   (Austria)

^h UNIVERSITY OF CAMBRIDGE   (United Kingdom)

ⁱ UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^j ADDENBROOKE S HOSPITAL   (United Kingdom)

^k Centro Nacional de Investigaciones Oncológicas   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CD31 ANTIGEN; CYCLIN D1; CYCLIN D3; CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE INHIBITOR 2A; VASCULOTROPIN A;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; B CELL LEUKEMIA; CANCER GROWTH; CELL CYCLE; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; FIBROBLAST; HISTONE MODIFICATION; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; TRANSCRIPTION REGULATION; TUMOR VASCULARIZATION; UPREGULATION;

EID: 84881528286     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2016.07.003     Document Type: Erratum

References (77)

1. Agger K., Cloos P.A., Rudkjaer L., Williams K., Andersen G., Christensen J., Helin K. The H3K27me3 demethylase JMJD3 contributes to the activation of the INK4A-ARF locus in response to oncogene- and stress-induced senescence. Genes Dev. 2009, 23:1171-1176.
2. Agirre X., Vilas-Zornoza A., Jiménez-Velasco A., Martin-Subero J.I., Cordeu L., Gárate L., San José-Eneriz E., Abizanda G., Rodríguez-Otero P., Fortes P., et al. Epigenetic silencing of the tumor suppressor microRNA Hsa-miR-124a regulates CDK6 expression and confers a poor prognosis in acute lymphoblastic leukemia. Cancer Res. 2009, 69:4443-4453.
3. Anders L., Ke N., Hydbring P., Choi Y.J., Widlund H.R., Chick J.M., Zhai H., Vidal M., Gygi S.P., Braun P., Sicinski P. A systematic screen for CDK4/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cells. Cancer Cell 2011, 20:620-634.
4. Barradas M., Anderton E., Acosta J.C., Li S., Banito A., Rodriguez-Niedenführ M., Maertens G., Banck M., Zhou M.M., Walsh M.J., et al. Histone demethylase JMJD3 contributes to epigenetic control of INK4a/ARF by oncogenic RAS. Genes Dev. 2009, 23:1177-1182.
5. Bienvenu F., Jirawatnotai S., Elias J.E., Meyer C.A., Mizeracka K., Marson A., Frampton G.M., Cole M.F., Odom D.T., Odajima J., et al. Transcriptional role of cyclin D1 in development revealed by a genetic-proteomic screen. Nature 2010, 463:374-378.
6. Bressac-de-Paillerets B., Avril M.F., Chompret A., Demenais F. Genetic and environmental factors in cutaneous malignant melanoma. Biochimie 2002, 84:67-74.
7. Brito-Babapulle V., Gruszka-Westwood A.M., Platt G., Andersen C.L., Elnenaei M.O., Matutes E., Wotherspoon A.C., Weston-Smith S.G., Catovsky D. Translocation t(2;7)(p12;q21-22) with dysregulation of the CDK6 gene mapping to 7q21-22 in a non-Hodgkin's lymphoma with leukemia. Haematologica 2002, 87:357-362.
8. Campisi J. Aging, cellular senescence, and cancer. Annu. Rev. Physiol. 2012, 75:685-705.
9. Cánepa E.T., Scassa M.E., Ceruti J.M., Marazita M.C., Carcagno A.L., Sirkin P.F., Ogara M.F. INK4 proteins, a family of mammalian CDK inhibitors with novel biological functions. IUBMB Life 2007, 59:419-426.
10. Chen D., Law M.E., Theis J.D., Gamez J.D., Caron L.B., Vrana J.A., Dogan A. Clinicopathologic features of CDK6 translocation-associated B-cell lymphoproliferative disorders. Am. J. Surg. Pathol. 2009, 33:720-729.
11. Chiarle R., Gong J.Z., Guasparri I., Pesci A., Cai J., Liu J., Simmons W.J., Dhall G., Howes J., Piva R., Inghirami G. NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors. Blood 2003, 101:1919-1927.
12. Chilosi M., Doglioni C., Yan Z., Lestani M., Menestrina F., Sorio C., Benedetti A., Vinante F., Pizzolo G., Inghirami G. Differential expression of cyclin-dependent kinase 6 in cortical thymocytes and T-cell lymphoblastic lymphoma/leukemia. Am. J. Pathol. 1998, 152:209-217.
13. Choi Y.J., Li X., Hydbring P., Sanda T., Stefano J., Christie A.L., Signoretti S., Look A.T., Kung A.L., von Boehmer H., Sicinski P. The requirement for cyclin D function in tumor maintenance. Cancer Cell 2012, 22:438-451.
14. Cicenas J., Valius M. The CDK inhibitors in cancer research and therapy. J. Cancer Res. Clin. Oncol. 2011, 137:1409-1418.
15. Classon M., Harlow E. The retinoblastoma tumour suppressor in development and cancer. Nat. Rev. Cancer 2002, 2:910-917.
16. Cordon-Cardo C. Mutations of cell cycle regulators. Biological and clinical implications for human neoplasia. Am. J. Pathol. 1995, 147:545-560.
17. Deshpande A., Sicinski P., Hinds P.W. Cyclins and cdks in development and cancer: a perspective. Oncogene 2005, 24:2909-2915.
18. Despouy G., Bastie J.N., Deshaies S., Balitrand N., Mazharian A., Rochette-Egly C., Chomienne C., Delva L. Cyclin D3 is a cofactor of retinoic acid receptors, modulating their activity in the presence of cellular retinoic acid-binding protein II. J.Biol. Chem. 2003, 278:6355-6362.
19. Ekholm S.V., Reed S.I. Regulation of G(1) cyclin-dependent kinases in the mammalian cell cycle. Curr. Opin. Cell Biol. 2000, 12:676-684.
20. Ericson K.K., Krull D., Slomiany P., Grossel M.J. Expression ofcyclin-dependent kinase 6, but not cyclin-dependent kinase 4, alters morphology of cultured mouse astrocytes. Mol. Cancer Res. 2003, 1:654-664.
21. Ferrara N., Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr. Rev. 1997, 18:4-25.
22. Fizzotti M., Cimino G., Pisegna S., Alimena G., Quartarone C., Mandelli F., Pelicci P.G., Lo Coco F. Detection of homozygous deletions of the cyclin-dependent kinase 4 inhibitor (p16) gene in acute lymphoblastic leukemia and association with adverse prognostic features. Blood 1995, 85:2685-2690.
23. Fry D.W., Harvey P.J., Keller P.R., Elliott W.L., Meade M., Trachet E., Albassam M., Zheng X., Leopold W.R., Pryer N.K., Toogood P.L. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol. Cancer Ther. 2004, 3:1427-1438.
24. Goldstein A.M., Chan M., Harland M., Gillanders E.M., Hayward N.K., Avril M.F., Azizi E., Bianchi-Scarra G., Bishop D.T., Bressac-de Paillerets B., et al. High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL. Cancer Res. 2006, 66:9818-9828. Melanoma Genetics Consortium (GenoMEL).
25. Gonzalez S., Klatt P., Delgado S., Conde E., Lopez-Rios F., Sanchez-Cespedes M., Mendez J., Antequera F., Serrano M. Oncogenic activity of Cdc6 through repression of the INK4/ARF locus. Nature 2006, 440:702-706.
26. Grossel M.J., Hinds P.W. Beyond the cell cycle: a new role for Cdk6 in differentiation. J. Cell. Biochem. 2006, 97:485-493.
27. Grossel M.J., Baker G.L., Hinds P.W. cdk6 can shorten G(1) phase dependent upon the N-terminal INK4 interaction domain. J.Biol. Chem. 1999, 274:29960-29967.
28. Hackanson B., Guo Y., Lübbert M. The silence of the genes: epigenetic disturbances in haematopoietic malignancies. Expert Opin. Ther. Targets 2005, 9:45-61.
29. Hayette S., Tigaud I., Callet-Bauchu E., Ffrench M., Gazzo S., Wahbi K., Callanan M., Felman P., Dumontet C., Magaud J.P., Rimokh R. In B-cell chronic lymphocytic leukemias, 7q21 translocations lead to overexpression of the CDK6 gene. Blood 2003, 102:1549-1550.
30. Hebert J., Cayuela J.M., Berkeley J., Sigaux F. Candidate tumor-suppressor genes MTS1 (p16INK4A) and MTS2 (p15INK4B) display frequent homozygous deletions in primary cells from T- but not from B-cell lineage acute lymphoblastic leukemias. Blood 1994, 84:4038-4044.
31. Hennessy B.T., Garcia-Manero G., Kantarjian H.M., Giles F.J. DNA methylation in haematological malignancies: the role of decitabine. Expert Opin. Investig. Drugs 2003, 12:1985-1993.
32. Hu M.G., Deshpande A., Enos M., Mao D., Hinds E.A., Hu G.F., Chang R., Guo Z., Dose M., Mao C., et al. A requirement for cyclin-dependent kinase 6 in thymocyte development and tumorigenesis. Cancer Res. 2009, 69:810-818.
33. Jirawatnotai S., Hu Y., Michowski W., Elias J.E., Becks L., Bienvenu F., Zagozdzon A., Goswami T., Wang Y.E., Clark A.B., et al. A function for cyclin D1 in DNA repair uncovered by protein interactome analyses in human cancers. Nature 2011, 474:230-234.
34. Kees U.R., Burton P.R., Lü C., Baker D.L. Homozygous deletion of the p16/MTS1 gene in pediatric acute lymphoblastic leukemia is associated with unfavorable clinical outcome. Blood 1997, 89:4161-4166.
35. Kim J.K., Diehl J.A. Nuclear cyclin D1: an oncogenic driver in human cancer. J. Cell. Physiol. 2009, 220:292-296.
36. Kollmann K., Heller G., Ott R.G., Scheicher R., Zebedin-Brandl E., Schneckenleithner C., Simma O., Warsch W., Eckelhart E., Hoelbl A., et al. c-JUN promotes BCR-ABL-induced lymphoid leukemia by inhibiting methylation of the 5' region of Cdk6. Blood 2011, 117:4065-4075.
37. Kollmann K., Heller G., Sexl V. c-JUN prevents methylation of p16(INK4a) (and Cdk6): the villain turned bodyguard. Oncotarget 2011, 2:422-427.
38. Kozar K., Sicinski P. Cell cycle progression without cyclin D-CDK4 and cyclin D-CDK6 complexes. Cell Cycle 2005, 4:388-391.
39. Landis M.W., Pawlyk B.S., Li T., Sicinski P., Hinds P.W. Cyclin D1-dependent kinase activity in murine development and mammary tumorigenesis. Cancer Cell 2006, 9:13-22.
40. Li Z., Jiao X., Wang C., Shirley L.A., Elsaleh H., Dahl O., Wang M., Soutoglou E., Knudsen E.S., Pestell R.G. Alternative cyclin D1 splice forms differentially regulate the DNA damage response. Cancer Res. 2010, 70:8802-8811.
41. Lien H.C., Lin C.W., Huang P.H., Chang M.L., Hsu S.M. Expression of cyclin-dependent kinase 6 (cdk6) and frequent loss of CD44 in nasal-nasopharyngeal NK/T-cell lymphomas: comparison with CD56-negative peripheral T-cell lymphomas. Lab. Invest. 2000, 80:893-900.
42. Lim J.T., Mansukhani M., Weinstein I.B. Cyclin-dependent kinase 6 associates with the androgen receptor and enhances its transcriptional activity in prostate cancer cells. Proc. Natl. Acad. Sci. USA 2005, 102:5156-5161.
43. Malumbres M. Cell cycle-based therapies move forward. Cancer Cell 2012, 22:419-420.
44. Malumbres M., Barbacid M. To cycle or not to cycle: a critical decision in cancer. Nat. Rev. Cancer 2001, 1:222-231.
45. Malumbres M., Barbacid M. Is cyclin D1-CDK4 kinase a bona fide cancer target?. Cancer Cell 2006, 9:2-4.
46. Malumbres M., Sotillo R., Santamaría D., Galán J., Cerezo A., Ortega S., Dubus P., Barbacid M. Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6. Cell 2004, 118:493-504.
47. Mao X., Orchard G., Lillington D.M., Russell-Jones R., Young B.D., Whittaker S.J. Amplification and overexpression of JUNB is associated with primary cutaneous T-cell lymphomas. Blood 2003, 101:1513-1519.
48. Matsushime H., Quelle D.E., Shurtleff S.A., Shibuya M., Sherr C.J., Kato J.Y. D-type cyclin-dependent kinase activity in mammalian cells. Mol. Cell. Biol. 1994, 14:2066-2076.
49. Musgrove E.A., Caldon C.E., Barraclough J., Stone A., Sutherland R.L. Cyclin D as a therapeutic target in cancer. Nat. Rev. Cancer 2011, 11:558-572.
50. Nagel S., Leich E., Quentmeier H., Meyer C., Kaufmann M., Drexler H.G., Zettl A., Rosenwald A., MacLeod R.A. Amplification at 7q22 targets cyclin-dependent kinase 6 in T-cell lymphoma. Leukemia 2008, 22:387-392.
51. Neufeld G., Cohen T., Gengrinovitch S., Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 1999, 13:9-22.
52. Niu G., Wright K.L., Huang M., Song L., Haura E., Turkson J., Zhang S., Wang T., Sinibaldi D., Coppola D., et al. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 2002, 21:2000-2008.
53. Nobori T., Miura K., Wu D.J., Lois A., Takabayashi K., Carson D.A. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 1994, 368:753-756.
54. Ott R.G., Simma O., Kollmann K., Weisz E., Zebedin E.M., Schorpp-Kistner M., Heller G., Zöchbauer S., Wagner E.F., Freissmuth M., Sexl V. JunB is a gatekeeper for B-lymphoid leukemia. Oncogene 2007, 26:4863-4871.
55. Parker E.P., Siebert R., Oo T.H., Schneider D., Hayette S., Wang C. Sequencing of t(2;7) translocations reveals a consistent breakpoint linking cdk6 to the igk@ locus in indolent b-cell neoplasia. J.Mol. Diagn. 2012, 15:101-109.
56. Passegué E., Wagner E.F. JunB suppresses cell proliferation by transcriptional activation of p16(INK4a) expression. EMBO J. 2000, 19:2969-2979.
57. Pavletich N.P. Mechanisms of cyclin-dependent kinase regulation: structures of Cdks, their cyclin activators, and Cip and INK4 inhibitors. J.Mol. Biol. 1999, 287:821-828.
58. Ray B.K., Shakya A., Ray A. Vascular endothelial growth factor expression in arthritic joint is regulated by SAF-1 transcription factor. J.Immunol. 2007, 178:1774-1782.
59. Reddy H.K., Mettus R.V., Rane S.G., Graña X., Litvin J., Reddy E.P. Cyclin-dependent kinase 4 expression is essential for neu-induced breast tumorigenesis. Cancer Res. 2005, 65:10174-10178.
60. Rodriguez-Otero P., Román-Gómez J., Vilas-Zornoza A., José-Eneriz E.S., Martín-Palanco V., Rifón J., Torres A., Calasanz M.J., Agirre X., Prosper F. Deregulation of FGFR1 and CDK6 oncogenic pathways in acute lymphoblastic leukaemia harbouring epigenetic modifications of the MIR9 family. Br. J. Haematol. 2011, 155:73-83.
61. Ruas M., Peters G. The p16INK4a/CDKN2A tumor suppressor and its relatives. Biochim. Biophys. Acta 1998, 1378:F115-F177.
62. Sabir M., Baig R.M., Mahjabeen I., Kayani M.A. Novel germline CDK4 mutations in patients with head and neck cancer. Hered. Cancer Clin. Pract. 2012, 10:11.
63. Sawai C.M., Freund J., Oh P., Ndiaye-Lobry D., Bretz J.C., Strikoudis A., Genesca L., Trimarchi T., Kelliher M.A., Clark M., et al. Therapeutic targeting of the cyclin D3:CDK4/6 complex in Tcell leukemia. Cancer Cell 2012, 22:452-465.
64. Schmidt D., Textor B., Pein O.T., Licht A.H., Andrecht S., Sator-Schmitt M., Fusenig N.E., Angel P., Schorpp-Kistner M. Critical role for NF-kappaB-induced JunB in VEGF regulation and tumor angiogenesis. EMBO J. 2007, 26:710-719.
65. Schwartz R., Engel I., Fallahi-Sichani M., Petrie H.T., Murre C. Gene expression patterns define novel roles for E47 in cell cycle progression, cytokine-mediated signaling, and T lineage development. Proc. Natl. Acad. Sci. USA 2006, 103:9976-9981.
66. Serrano M., Lee H., Chin L., Cordon-Cardo C., Beach D., DePinho R.A. Role of the INK4a locus in tumor suppression and cell mortality. Cell 1996, 85:27-37.
67. Sherr C.J., Roberts J.M. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 1999, 13:1501-1512.
68. Shinkai Y., Rathbun G., Lam K.P., Oltz E.M., Stewart V., Mendelsohn M., Charron J., Datta M., Young F., Stall A.M., et al. RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. Cell 1992, 68:855-867.
69. Szremska A.P., Kenner L., Weisz E., Ott R.G., Passegué E., Artwohl M., Freissmuth M., Stoxreiter R., Theussl H.C., Parzer S.B., et al. JunB inhibits proliferation and transformation in B-lymphoid cells. Blood 2003, 102:4159-4165.
70. Vidal A., Koff A. Cell-cycle inhibitors: three families united by a common cause. Gene 2000, 247:1-15.
71. Wölfel T., Hauer M., Schneider J., Serrano M., Wölfel C., Klehmann-Hieb E., De Plaen E., Hankeln T., Meyer zum Büschenfelde K.H., Beach D. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 1995, 269:1281-1284.
72. Wong K.Y., So C.C., Loong F., Chung L.P., Lam W.W., Liang R., Li G.K., Jin D.Y., Chim C.S. Epigenetic inactivation of the miR-124-1 in haematological malignancies. PLoS ONE 2011, 6:e19027.
73. Yang M.Y., Liu T.C., Chang J.G., Lin P.M., Lin S.F. JunB gene expression is inactivated by methylation in chronic myeloid leukemia. Blood 2003, 101:3205-3211.
74. Yin Y., Wang S., Sun Y., Matt Y., Colburn N.H., Shu Y., Han X. JNK/AP-1 pathway is involved in tumor necrosis factor-alpha induced expression of vascular endothelial growth factor in MCF7 cells. Biomed. Pharmacother. 2009, 63:429-435.
75. Zacharek S.J., Xiong Y., Shumway S.D. Negative regulation of TSC1-TSC2 by mammalian D-type cyclins. Cancer Res. 2005, 65:11354-11360.
76. Zhao J.J., Lin J., Lwin T., Yang H., Guo J., Kong W., Dessureault S., Moscinski L.C., Rezania D., Dalton W.S., et al. microRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma. Blood 2010, 115:2630-2639.
77. Zou X., Ray D., Aziyu A., Christov K., Boiko A.D., Gudkov A.V., Kiyokawa H. Cdk4 disruption renders primary mouse cells resistant to oncogenic transformation, leading to Arf/p53-independent senescence. Genes Dev. 2002, 16:2923-2934.